The Greenwall Foundation convened a group of bioethics experts who explored recent issues and controversies surrounding the U.S. Food and Drug Administration, such as the agency’s approval of the Alzheimer’s drug Aduhelm, the role of advisory committees, tobacco regulation, COVID-19 vaccine approvals, and more. With moderator Adam Feuerstein, senior writer for STAT news, the panelists also explored what is needed to restore trust in the FDA.
This panel marked the 20th Anniversary of The Greenwall Foundation’s flagship Faculty Scholars Program. The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. It awards approximately $3-4 million annually in support of its mission to expand bioethics knowledge to improve clinical, biomedical, and public health decision-making, policy, and practice.
To learn more about the Foundation, visit greenwall.org
30 сен 2024
